Gothenburg, Sweden, 30 May 2011: Denator AB announced today that Dr. Martin Nicklasson has been appointed as a new Board Member with immediate effect.
Dr Nicklasson has over 30 years’ experience in the pharmaceutical industry, holding senior executive management positions over the past 20 years such as CEO at Astra Zeneca AB,
Chairman of the board at Astra Tech and CEO at Biovitrum AB. Most recently, he served as President and CEO for Swedish Orphan Biovitrum AB (SOBI). Dr Nicklasson is currently a board member of, amongst others, the Swedish Heart & Lung Foundation, Scandinavian Life Science Invest AB and Biocrine AB.
Olof Sköld, CEO at Denator stated, “We are delighted to welcome Dr. Nicklasson to our Board. His extensive knowledge, experience and proven expertise in the pharmaceutical industry, one of our most important market segments, will be a very valuable addition to our company.”
About Denator AB
www.denator.com
Denator AB is a privately held biotech company based in Gothenburg, Sweden. Denator develops and markets products that stabilize biological tissues and fluids from the moment of sampling. Stabilization and standardization of sampling processes upstream significantly enhances the quality of data obtained from analytical techniques used downstream. Based upon the company’s proprietary heat inactivation technology platform, Denator is developing solutions that enable scientists to stop sample degradation instantly and so maintain the stability of sample components throughout the analytical workflow.
